Abstract
The development of cerebrospinal fluid (CSF) biomarkers for Alzheimer’s disease (AD) and related disorders is rapidly progressing. Although the use of precision medicine methods has contributed to enhanced understanding of the AD pathophysiological changes and development of assays, one aspect not commonly considered is sex and gender differences. There are several ways in which sex can affect the measurement or interpretation of AD-related CSF biomarkers, including sex differences in biomarker concentrations and sex differences in the diagnosis or prognosis of the biomarker. This chapter highlights the impetus to consider sex differences in the development and interpretation of clinical assays for CSF biomarkers of AD.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
